Increased Excretion of Modified Adenine Nucleosides by Children with Adenosine Dearninase Deficiency

Total Page:16

File Type:pdf, Size:1020Kb

Increased Excretion of Modified Adenine Nucleosides by Children with Adenosine Dearninase Deficiency Pediatr. Res. 16: 362-369 (1982) Increased Excretion of Modified Adenine Nucleosides by Children with Adenosine Dearninase Deficiency ROCHELLE HIRSCHHORN,'"~ HOWARD RATECH, ARYE RUBINSTEIN, PHOTINI PAPAGEORGIOU, HERNANT KESARWALA, ERWIN GELFAND, AND VIVIEN ROEGNER-MANISCALCO Departments of Medicine and Pathology, New York University School of Medicine, New York, New York [R.H., H.R., and V.R.-M.];Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York [A.R.]; Department of Pediatrics, Rutgers University Medical ~chool,Piscataway, New Jersey [P.P., and H.K.]; and Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada [E. G.] Summary tially in, and prevents proliferation of, irnmunocompetent cells, primarily of the T cell class (2, 5, 6, 23, 38, 49, 54). There is also We have identified seven adenine nucleosides in urines of un- in vivo and/or in vitro evidence for alternative mechanisms of treated adenosine deaminase (ADA) deficient patients, four of toxicity, which would operate via depletion of pyrimidine pools, which (adenosine, 2'-deoxyadenosine, 1-methyladenosine and N6- depletion of phosphoribosyl pyrophosphate and increases in cyclic methyladenosine) have been previously identified in urines of AMP or S-adenosyl homocysteine (16, 21, 24, 40, 46, 55). All of normals and/or ADA deficient patients. We confirm that ADA these mechanisms are dependent on accumulation of the substrates deficient patients excrete markedly increased amounts of 2'-deox- of ADA, adenosine and 2'-deoxyadenosine. yadenosine (582 k 363 versus normal of < 0.1 nmoles/mg creati- In addition to adenosine and 2'-deoxyadenosine, several other nine) and increased amounts of adenosine (29.4 & 5.7 versus modified adenine nucleosides occur naturally (17, 19) and are normal of 4.12 & 1.0 nmoles/mg creatinine). substrates for ADA (1, 18, 43, 56). Such naturally occurring We have found three other modified adenine nucleosides previ- modified adenine nucleosides might be expected to also accumu- ously undetected in human urine. These three compounds are 2'- late in ADA deficient patients and possibly contribute to toxicity. 0-methyladenosine, N6, 2'-O-dimethyladenosine and an as yet incompletely characterized modified adenine nucleoside, R-aden- We have, therefore, sought to determine if these modified adenine nucleosides are uniquely present, or present in increased amounts, osine. Only ADA deficient patients excrete detectable amounts of in urine of ADA deficient patients. We have identified seven 2'-0-methyladenosine (2.1 1.1 versus normal of < 0.1 nmoles/ + compounds in urines of ADA deficients, four of which (adenosine, mg creatinine), whereas both normals and ADA deficient children excrete N6, 2'-Odimethyladenosine and R-adenosine. However, 2'-deoxyadenosine, 1-methyladenosine and N"methy1adenosine) have been previously identified in urines of normals and/or ADA ADA deficient patients do excrete increased amounts of R-aden- deficient patients (4,9,27,28,32,36,37,50). We have additionally osine (5.5 1.0 versus normal of 1.4 k 0.4 nmoles/mg creatinine). + found three other substrates of ADA not ~reviouslvdetected in urine. These three compounds newly identified in urine are 2'-0- Speculation methyladenosine, N6,2'-0-dimethyladenosine and an as yet in- Accumulation in ADA deficient patients of two newly detected completely characterized modified adenine nucleoside, R-adeno- modified adenine nucleosides (2'-0-methyladenosine and R-aden- sine. Only ADA deficient patients excrete detectable amounts of osine) or their metabolites could play a role in explaining the 2'-0-methyladenosine, whereas both normal and ADA deficient profound abnormalities of B cell function seen in ADA deficiency children excrete N"2'-0-dimethyladenosine and the as yet uni- but not in purine nucleoside phosphorylase deficiency. This differ- dentified ADA substrate R-adenosine. However, ADA deficient ential involvement of B cell function is not easily explained by patients excrete increased amounts of R-adenosine. accumulation of deoxytrinucleotides, which occurs in both disor- ders. MATERIALS AND METHODS Materials. Nucleosides were obtained from Sigma Co. (St. Inherited deficiency of the purine salvage enzyme, adenosine Louis, MO) or P&L (Milwaukee, WI). 2'-0-Methylinosine was deaminase (ADA) results in a fatal infantile syndrome of severe generated by incubation of 2'-0-methyladenosine with calf intes- combined immunodeficiency (ADA-SCID) (10, 15, 22, 25, 30). tinal ADA, type I from Sigma, and purified by high pressure Children with ADA deficiency have a profound defect in both liquid chromatography. 5'-Methylthioadenosine was generated by cellular and humoral immunity, although in 10-15% of cases, the acid hydrolysis of ,S-adenosyl methionine (45). 5'-deoxyadenosine humoral defect may initially be less severe (22). Affected children and N~threonino~arbon~ladenosine were the generous gifts of accumulate and/or excrete markedly increasd amounts of the respectively Dr. G. Elion and Dr. G.B. Chheda. ADA substrates, adenosine and 2'-deoxyadenosine, and the phos- Anion exchange chromatography. Urines (stored frozen at phorylated metabolite, deoxy ATP (dATP) (3, 5, 6, 9, 26-28, 32, -70 "C with 0.01% sodium azide) were chromatographed on an 37, 41, 46, 50). anion exchange column (Biorad AG I-X2, Richmond, CA) essen- Several pathophysiologic mechanisms have been proposed tially as described by Kuttesch, et al. (32) except that four fractions whereby accumulation of ADA substrates and their metabolites were collected. Fraction 1, 1-6 ml; fraction 2, 7-3 1 ml; fraction 3, would result in immunodeficiency (5, 12, 15, 16, 21, 24, 40, 52). 32-52 ml and fraction 4, 53-73 ml (eluting after the addition of The largest body of evidence supports the hypothesis that ~ATP, acid). Adenosine and 2'-deoxyadenosine eluted in fraction 2 and an inhibitor of ribonucleotide reductase, accumulates preferen- adenine in fraction 4, as previously described (32, 36). The elution ADENOSINE DEAMINASE DEFICIENCY 363 profiles of several authentic compounds, including modified ade- Peak shifi and acid hydrolysis. Samples and authentic com- nine and guanine nucleosides and bases are shown in Figure I. pounds were incubated with and without calf intestinal ADA High pressure liquid chromarography (HPLC).Urines (fraction- (Sigma Type 1, St. Lfiuis, MO) (20,42) at 0.08, 1.5 and 15 IU/ml ated and unfractionated) were analyzed by HPLC on C 18 pBon- final concentration for 1-2 h at 37OC and then analyzed by HPLC dapak columns (Waters Co., Milford, MA) by methods previously (Fig. 2 and Table 1). For hydrolysis of nucleosides to bases, peaks described (42) except that the gradient went from 0 to 40% of interest were collected by HPLC, concentrated, reconstituted methanol in 60 min. For further identification, peaks of interest with H20 and an aliquot boiled for 30 min in 0.45 N perchloric were collected, dried under nitrogen, reconstituted with water, and acid and neutralized with KOH. The authentic compounds aden- reanalyzed following either treatment with ADA, acid hydrolysis osine, 2'-deoxyadenosine, 2'-0-methyladenosine, N6-methylad- or chromatography on Afigel601 (Biorad, Richmond, CA). UV enosine, I-methyladenosine, N6,N6,-dimethyladenosineand N6- ratios of compounds were determined by simultaneous monitoring isopentenyladenosine were hydrolyzed under the same conditions at the two wavelengths specified. Retention times of relevant and the reaction products analyzed by HPLC. Nz-methylguano- nucleosides and bases are listed in Table 1. sine eluted in the last of the anion exchange fractions (Fig. I) and 0-0 INOSINE r-• N6UETHYL ADENOSINE ( 0-0 OEOXYINOSINE &-d NsH( DIuETnYL ADENOSINE ' W GUANOSINE )-8 2'0 METHYL ADENOSINE r-r GUANINE 0-0 7 METnlL GUlNOSlNE , B--B N~UETHIL GUINOSlNE I - NIM DIMETHYL GUANOS~NEI 4 8 12 16 20 24 28 JL56 60 64 68 72 74 ELUTION VOLUME (ml) Fig. I. Elution of methylated nucleosides from dowex AG I X2. Authentic compounds were diluted and chromatographed on Dowex AG I X2 columns as described in "Materials and Methods". All the modified adenine nucleosides tested (as well as adenosine) eluted in the sewnd fraction except for I-methyladenosine which eluted in the first and sewnd fractions. Isopentenyl adenosine could not be recovered by this method (not shown). Table 1. Relative retention times of mod$ed adenine nucleosides and the products generared by deamination or acid hydrolysis Retention time Retention time2 Retention time2 Retention time Deamination Retention time Retention time Compound Adenosine product Inosine Hydrolysis product Adenin I-Methyladenosine' Adenosine' inosine adenine 2'-Deoxyadenosine' 2'-deoxyinosine adenine N" threonino~arbon~ladeno- NT' NT sine 5'-Deoxyadenosine 5'-deoxyinosine adenine R-adenosine' R-inosine R-adenine 2'-0-Methyladenosine' 2'-0-methylinosine adenine N6-Methyladenosine' inosine N6-methyladenine 3'-0-Methyladenosine 3'-0-methylinosine adenine ~",2'-0-Dimethyladenosine' 2'-0-methylinosine adenine N"N"-Dimethyladenosine inosine N"N6,-dimethyladenine lsopentenyladenosine inosine "isopenteny ladenineW3 5'-Methylthioadenosine NT NT Adenosine N'-oxide NT NT 2-Methyladenosine NT 2-methyladenine - -- ' Compounds isolated from urine as well as authentic compounds, treated with ADA and also acid hydrolyzed. Retention times of urinary compounds were identical to those of the authentic wmpounds, as determined by coelution. Inosine and adenine have retention time relative to adenosine (1.00) of 0.58 and 0.70. All closely eluting
Recommended publications
  • REDUCTION of PURINE CONTENT in COMMONLY CONSUMED MEAT PRODUCTS THROUGH RINSING and COOKING by Anna Ellington (Under the Directio
    REDUCTION OF PURINE CONTENT IN COMMONLY CONSUMED MEAT PRODUCTS THROUGH RINSING AND COOKING by Anna Ellington (Under the direction of Yen-Con Hung) Abstract The commonly consumed meat products ground beef, ground turkey, and bacon were analyzed for purine content before and after a rinsing treatment. The rinsing treatment involved rinsing the meat samples using a wrist shaker in 5:1 ratio water: sample for 2 or 5 minutes then draining or centrifuging to remove water. The total purine content of 25% fat ground beef significantly decreased (p<0.05) from 8.58 mg/g protein to a range of 5.17-7.26 mg/g protein after rinsing treatments. After rinsing and cooking an even greater decrease was seen ranging from 4.59-6.32 mg/g protein. The total purine content of 7% fat ground beef significantly decreased from 7.80 mg/g protein to a range of 5.07-5.59 mg/g protein after rinsing treatments. A greater reduction was seen after rinsing and cooking in the range of 4.38-5.52 mg/g protein. Ground turkey samples showed no significant changes after rinsing, but significant decreases were seen after rinsing and cooking. Bacon samples showed significant decreases from 6.06 mg/g protein to 4.72 and 4.49 after 2 and 5 minute rinsing and to 4.53 and 4.68 mg/g protein after 2 and 5 minute rinsing and cooking. Overall, this study showed that rinsing foods in water effectively reduces total purine content and subsequent cooking after rinsing results in an even greater reduction of total purine content.
    [Show full text]
  • Deoxyguanosine Cytotoxicity by a Novel Inhibitor of Furine Nucleoside Phosphorylase, 8-Amino-9-Benzylguanine1
    [CANCER RESEARCH 46, 519-523, February 1986] Potentiation of 2'-Deoxyguanosine Cytotoxicity by a Novel Inhibitor of Furine Nucleoside Phosphorylase, 8-Amino-9-benzylguanine1 Donna S. Shewach,2 Ji-Wang Chern, Katherine E. Pillóte,Leroy B. Townsend, and Peter E. Daddona3 Departments of Internal Medicine [D.S.S., P.E.D.], Biological Chemistry [P.E.D.], and Medicinal Chemistry [J-W.C., K.E.P., L.B.T.], University ol Michigan, Ann Arbor, Michigan 48109 ABSTRACT to the ADA-deficient disease state (2). PNP is an essential enzyme of the purine salvage pathway, We have synthesized and evaluated a series of 9-substituted catalyzing the phosphorolysis of guanosine, inosine, and their analogues of 8-aminoguanine, a known inhibitor of human purine 2'-deoxyribonucleoside derivatives to the respective purine nucleoside phosphorylase (PNP) activity. The ability of these bases. To date, several inhibitors of PNP have been identified, agents to inhibit PNP has been investigated. All compounds were and most of these compounds resemble purine bases or nucleo found to act as competitive (with inosine) inhibitors of PNP, with sides. The most potent inhibitors exhibit apparent K¡values in K¡values ranging from 0.2 to 290 /¿M.Themost potent of these the range of 10~6to 10~7 M (9-12). Using partially purified human analogues, 8-amino-9-benzylguanine, exhibited a K, value that erythrocyte PNP, the diphosphate derivative of acyclovir dis was 4-fold lower than that determined for the parent base, 8- played K¡values of 5.1 x 10~7 to 8.7 x 10~9 M, depending on aminoguanine.
    [Show full text]
  • Investigation of Overhauser Effects Between Pseudouridine and Water Protons in RNA Helices
    Investigation of Overhauser effects between pseudouridine and water protons in RNA helices Meredith I. Newby* and Nancy L. Greenbaum*†‡ *Department of Chemistry and Biochemistry and †Institute of Molecular Biophysics, Florida State University, Tallahassee, FL 32306-4390 Communicated by Michael Kasha, Florida State University, Tallahassee, FL, August 8, 2002 (received for review July 2, 2002) The inherent chemical properties of RNA molecules are expanded by posttranscriptional modification of specific nucleotides. Pseudouridine (␺), the most abundant of the modified bases, features an additional imino group, NH1, as compared with uri- dine. When ␺ forms a Watson–Crick base pair with adenine in an RNA helix, NH1 is positioned within the major groove. The pres- ence of ␺ often increases thermal stability of the helix or loop in which it is found [Hall, K. B. & McLaughlin, L. (1992) Nucleic Acids Res. 20, 1883–1889]. X-ray crystal structures of transfer RNAs [e.g., Arnez, J. & Steitz, T. (1994) Biochemistry 33, 7560–7567] have depicted water molecules bridging ␺NH1 groups and nearby phos- phate oxygen atoms, but direct evidence for this interaction in solution has not been acquired. Toward this end, we have used a rotating-frame Overhauser effect spectroscopy-type NMR pulse sequence with a CLEAN chemical-exchange spectroscopy spin-lock pulse train [Hwang, T.-L., Mori, S., Shaka, A. J. & van Zijl, P. C. M. Fig. 1. Schematic structures of U and ␺ bases. R, ribose. The ␺ base is a uracil ␺ (1997) J. Am. Chem. Soc. 119, 6203–6204] to test for NH1–water rotated about the 3–6 ring axis, so that is has a COC base–sugar linkage and cross-relaxation effects within two RNA helices: (i) a complemen- an additional protonated ring nitrogen.
    [Show full text]
  • Adenine-Based Purines and Related Metabolizing Enzymes: Evidence for Their Impact on Tumor Extracellular Vesicle Activities
    cells Review Adenine-Based Purines and Related Metabolizing Enzymes: Evidence for Their Impact on Tumor Extracellular Vesicle Activities Patrizia Di Iorio 1,2 and Renata Ciccarelli 1,2,* 1 Department of Medical, Oral and Biotechnological Sciences, ‘G. D’Annunzio’ University of Chieti-Pescara, 66100 Chieti, Italy; [email protected] 2 Center for Advanced Studies and Technology (CAST), ‘G. D’Annunzio’ University of Chieti-Pescara, 66100 Chieti, Italy * Correspondence: [email protected] Abstract: Extracellular vesicles (EVs), mainly classified as small and large EVs according to their size/origin, contribute as multi-signal messengers to intercellular communications in normal/pathological conditions. EVs are now recognized as critical players in cancer processes by promoting transformation, growth, invasion, and drug-resistance of tumor cells thanks to the release of molecules contained inside them (i.e., nucleic acids, lipids and proteins) into the tumor microenvironment (TME). Interestingly, secre- tion from donor cells and/or uptake of EVs/their content by recipient cells are regulated by extracellular signals present in TME. Among those able to modulate the EV-tumor crosstalk, purines, mainly the adenine-based ones, could be included. Indeed, TME is characterized by high levels of ATP/adenosine and by the presence of enzymes deputed to their turnover. Moreover, ATP/adenosine, interacting with their own receptors, can affect both host and tumor responses. However, studies on whether/how the purinergic system behaves as a modulator of EV biogenesis, release and functions in cancer are still poor. Thus, this review is aimed at collecting data so far obtained to stimulate further research in this regard.
    [Show full text]
  • Cyclic Nucleotide Phosphodiesterases in Heart and Vessels
    Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective Pierre Bobin, Milia Belacel-Ouari, Ibrahim Bedioune, Liang Zhang, Jérôme Leroy, Véronique Leblais, Rodolphe Fischmeister, Grégoire Vandecasteele To cite this version: Pierre Bobin, Milia Belacel-Ouari, Ibrahim Bedioune, Liang Zhang, Jérôme Leroy, et al.. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2016, 109 (6-7), pp.431-443. 10.1016/j.acvd.2016.02.004. hal-02482730 HAL Id: hal-02482730 https://hal.archives-ouvertes.fr/hal-02482730 Submitted on 23 Mar 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective Abbreviated title: Cyclic nucleotide phosphodiesterases in heart and vessels French title: Phosphodiestérases des nucléotides cycliques dans le cœur et les vaisseaux : une perspective thérapeutique. Pierre Bobin, Milia Belacel-Ouari, Ibrahim Bedioune, Liang Zhang, Jérôme Leroy, Véronique Leblais, Rodolphe Fischmeister*, Grégoire Vandecasteele* UMR-S 1180, INSERM, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France * Corresponding authors. UMR-S1180, Faculté de Pharmacie, Université Paris-Sud, 5 rue J.-B. Clément, F-92296 Châtenay-Malabry Cedex, France.
    [Show full text]
  • Inhibitory Effects of Cordycepin on Platelet Activation Via Regulation of Cyclic Adenosine Monophosphate-Downstream Pathway
    Biomedical Science Letters 2017, 23(3): 251~260 Original Article https://doi.org/10.15616/BSL.2017.23.3.251 eISSN : 2288-7415 Inhibitory Effects of Cordycepin on Platelet Activation via Regulation of Cyclic Adenosine Monophosphate-downstream Pathway Dong-Ha Lee† Department of Biomedical Laboratory Science, Korea Nazarene University, Cheonan 31172, Korea Platelet activation is essential at the sites of vascular injury, which leads to hemostasis through adhesion, aggregation, and secretion process. However, potent and continuous platelet activation may be an important reason of circulatory disorders. Therefore, proper regulation of platelet activation may be an effective treatment for vascular diseases. In this research, inhibitory effects of cordycepin (3'-deoxyadenosine) on platelet activation were determined. As the results, cordycepin increased cAMP and cGMP, which are intracellular Ca2+-antagonists. In addition, cordycepin reduced collagen- 2+ elevated [Ca ]i mobilization, which was increased by a cAMP-dependent protein kinase (PKA) inhibitor (Rp-8-Br- cAMPS), but not a cGMP-protein kinase (PKG) inhibitor (Rp-8-Br-cGMPS). Furthermore, cordycepin increased IP3RI 1756 2+ (Ser ) phosphorylation, indicating inhibition of IP3-mediated Ca release from internal store via the IP3RI, which was strongly inhibited by Rp-8-Br-cAMPS, but was not so much inhibited by Rp-8-Br-cGMPS. These results suggest that the 2+ 1756 reduction of [Ca ]i mobilization is caused by the cAMP/A-kinase-dependent IP3RI (Ser ) phosphorylation. In addition, cordycepin increased the phosphorylation of VASP (Ser157) known as PKA substrate, but not VASP (Ser239) known as PKG substrate. Cordycepin-induced VASP (Ser157) phosphorylation was inhibited by Rp-8-Br-cAMPS, but was not inhibited by Rp-8-Br-cGMPS, and cordycepin inhibited collagen-induced fibrinogen binding to αIIb/β3, which was increased by Rp-8-Br-cAMPS, but was not inhibited by Rp-8-Br-cGMPS.
    [Show full text]
  • The Human Ortholog of Archaeal Pus10 Produces Pseudouridine 54 in Select Trnas Where Its Recognition Sequence Contains a Modified Residue
    Downloaded from rnajournal.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press The human ortholog of archaeal Pus10 produces pseudouridine 54 in select tRNAs where its recognition sequence contains a modified residue MANISHA DEOGHARIA,1 SHAONI MUKHOPADHYAY, ARCHI JOARDAR,2 and RAMESH GUPTA Department of Biochemistry and Molecular Biology, Southern Illinois University, Carbondale, Illinois 62901-4413, USA ABSTRACT The nearly conserved U54 of tRNA is mostly converted to a version of ribothymidine (T) in Bacteria and eukaryotes and to a version of pseudouridine (Ψ) in Archaea. Conserved U55 is nearly always modified to Ψ55 in all organisms. Orthologs of TrmA and TruB that produce T54 and Ψ55, respectively, in Bacteria and eukaryotes are absent in Archaea. Pus10 produces both Ψ54 and Ψ55 in Archaea. Pus10 orthologs are found in nearly all sequenced archaeal and most eukaryal genomes, but not in yeast and bacteria. This coincides with the presence of Ψ54 in most archaeal tRNAs and some animal tRNAs, but its absence from yeast and bacteria. Moreover, Ψ54 is found in several tRNAs that function as primers for retroviral DNA syn- thesis. Previously, no eukaryotic tRNA Ψ54 synthase had been identified. We show here that human Pus10 can produce Ψ54 in select tRNAs, including tRNALys3, the primer for HIV reverse transcriptase. This synthase activity of Pus10 is restrict- ed to the cytoplasm and is distinct from nuclear Pus10, which is known to be involved in apoptosis. The sequence GUUCAm1AAUC (m1A is 1-methyladenosine) at position 53–61 of tRNA along with a stable acceptor stem results in max- imum Ψ54 synthase activity.
    [Show full text]
  • Pseudouridine Synthases Modify Human Pre-Mrna Co-Transcriptionally and Affect Splicing
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.29.273565; this version posted August 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect splicing Authors: Nicole M. Martinez1, Amanda Su1, Julia K. Nussbacher2,3,4, Margaret C. Burns2,3,4, Cassandra Schaening5, Shashank Sathe2,3,4, Gene W. Yeo2,3,4* and Wendy V. Gilbert1* Authors and order TBD with final revision. Affiliations: 1Yale School of Medicine, Department of Molecular Biophysics & Biochemistry, New Haven, CT 06520, USA. 2Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92037, USA. 3Stem Cell Program, University of California, San Diego, La Jolla, CA 92037, USA. 4Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92037, USA. 5Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. *Correspondence to: [email protected], [email protected] Abstract: Eukaryotic messenger RNAs are extensively decorated with modified nucleotides and the resulting epitranscriptome plays important regulatory roles in cells 1. Pseudouridine (Ψ) is a modified nucleotide that is prevalent in human mRNAs and can be dynamically regulated 2–5. However, it is unclear when in their life cycle RNAs become pseudouridylated and what the endogenous functions of mRNA pseudouridylation are. To determine if pseudouridine is added co-transcriptionally, we conducted pseudouridine profiling 2 on chromatin-associated RNA to reveal thousands of intronic pseudouridines in nascent pre-mRNA at locations that are significantly associated with alternatively spliced exons, enriched near splice sites, and overlap hundreds of binding sites for regulatory RNA binding proteins.
    [Show full text]
  • Questions with Answers- Nucleotides & Nucleic Acids A. the Components
    Questions with Answers- Nucleotides & Nucleic Acids A. The components and structures of common nucleotides are compared. (Questions 1-5) 1._____ Which structural feature is shared by both uracil and thymine? a) Both contain two keto groups. b) Both contain one methyl group. c) Both contain a five-membered ring. d) Both contain three nitrogen atoms. 2._____ Which component is found in both adenosine and deoxycytidine? a) Both contain a pyranose. b) Both contain a 1,1’-N-glycosidic bond. c) Both contain a pyrimidine. d) Both contain a 3’-OH group. 3._____ Which property is shared by both GDP and AMP? a) Both contain the same charge at neutral pH. b) Both contain the same number of phosphate groups. c) Both contain the same purine. d) Both contain the same furanose. 4._____ Which characteristic is shared by purines and pyrimidines? a) Both contain two heterocyclic rings with aromatic character. b) Both can form multiple non-covalent hydrogen bonds. c) Both exist in planar configurations with a hemiacetal linkage. d) Both exist as neutral zwitterions under cellular conditions. 5._____ Which property is found in nucleosides and nucleotides? a) Both contain a nitrogenous base, a pentose, and at least one phosphate group. b) Both contain a covalent phosphodister bond that is broken in strong acid. c) Both contain an anomeric carbon atom that is part of a β-N-glycosidic bond. d) Both contain an aldose with hydroxyl groups that can tautomerize. ___________________________________________________________________________ B. The structures of nucleotides and their components are studied. (Questions 6-10) 6._____ Which characteristic is shared by both adenine and cytosine? a) Both contain one methyl group.
    [Show full text]
  • Plasma Deoxyadenosine, Adenosine, and Erythrocyte Deoxyatp Are Elevated at Birth in an Adenosine Deaminase-Deficient Child
    Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient child. R Hirschhorn, … , A Rubinstein, P Papageorgiou J Clin Invest. 1980;65(3):768-771. https://doi.org/10.1172/JCI109725. Research Article We have determined concentrations of adenosine, deoxyadenosine, and deoxyATP (dATP) in cord blood from an infant prenatally diagnosed as ADA deficient. Plasma deoxyadenosine and adenosine were already elevated in cord blood (0.7 and 0.5 microM vs. normal of less than 0.07 microM). Elevation of plasma deoxyadenosine has not previously been documented in these children. Erythrocyte dATP content was also elevated at birth (215 nmol/ml packed erythrocytes vs. normal of 2.9). These elevated concentrations of adenosine, deoxyadenosine, and dATP are similar to those we observed in another older adenosine deaminase-deficient patient and may explain the impaired immune function and lymphopenia seen at birth. Find the latest version: https://jci.me/109725/pdf RAPID PUBLICATIONS Plasma Deoiyadenosine, Adenosine, and Erythrocyte deoxyATP are Elevated at Birth in an Adenosine Deaminase-deficient Child ROCHELLE HIRSCHHORN and VIVIAN ROEGNER, Department of Medicine, New York University School of Medicine, New York 10016 ARYE RUBINSTEIN, Department of Pediatrics, Albert Einstein College of Medicine, New York 10461 PHOTINI PAPAGEORGIOU, Department of Pediatrics, Rutgers University Medical School, New Brunswick, Netv Jersey 08854 A B S T RA C T We have determined concentrations of amounts of deoxyadenosine, another substrate of ADA, adenosine, deoxyadenosine, and deoxyATP (dATP) in in their urine (4-11). Additionally, deoxyATP (dATP), a cord blood from an infant prenatally diagnosed as ADA metabolite of deoxyadenosine, is markedly increased deficient.
    [Show full text]
  • Biochemical Basis for Differential Deoxyadenosine Toxicity To
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 5, pp. 2434-2437, May 1979 Medical Sciences Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: Role for 5'-nucleotidase (deoxyadenosine kinase/deoxyadenylate kinase/immunodeficiency) ROBERT L. WORTMANN, BEVERLY S. MITCHELL, N. LAWRENCE EDWARDS, AND IRVING H. Fox Human Purine Research Center, Departments of Internal Medicine and Biological Chemistry, Clinical Research Center, University of Michigan Medical Center, Ann Arbor, Michigan 48109 Communicated by James B. Wyngaarden, March 7, 1979 ABSTRACT Deoxyadenosine metabolism was investigated tained from Calbiochem. Erythro-9-[3-(2-hydroxynonyl)]- in cultured human cells to elucidate the biochemical basis for adenine (EHNA) was a gift from G. B. Elion of Burroughs the sensitivity of T lymphoblasts and the resistance of B lym- Wellcome (Research Triangle Park, NC). Horse serum was phoblasts to deoxyadenosine toxicity. T lymphoblasts have a 20- to 45-fold greater capacity to synthesize deoxyadenosine nu- obtained from Flow Laboratories (Rockville, MD), and Eagle's cleotides than B lymphoblasts at deoxyadenosine concentrations minimal essential medium was purchased from GIBCO. From of 50-300 ,uM. During the synthesis of dATP, T lymphoblasts Amersham/Searle, [U-14C]deoxyadenosine (505 mCi/mmol), accumulate large quantities of dADP, whereas B lymphoblasts [8-14C]hypoxanthine (52.5 mCi/mmol), and [U-14C]deoxy- do not accumu ate dADP. Enzymes affecting deoxyadenosine adenosine monophosphate (574 mCi/mmol) were purchased; nucleotide synthesis were assayed in these cells. No substantial and, from ICN, [8-14C]adenosine monophosphate (34.4 mCi/ differences were evident in activities of deoxyadenosine kinase (ATP: deoxyadenosine 5'-phosphotransferase, EC 2.7.1.76) or mmol) was purchased (1 Ci = 3.7 X 1010 becquerels).
    [Show full text]
  • A Dissertation Entitled Ribonucleic Acids in Disease Etiology and Drug Discovery by Immaculate Sappy Submitted to the Graduate F
    A Dissertation entitled Ribonucleic Acids in Disease Etiology and Drug Discovery by Immaculate Sappy Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Medicinal Chemistry ________________________________________ Amanda C. Bryant-Friedrich, Ph.D., Committee Chair ________________________________________ Zahoor A Shah, Ph.D., Committee Member ________________________________________ Steven M Peseckis, Ph.D., Committee Member ________________________________________ Caren Steinmiller, Ph.D., Committee Member ________________________________________ Amanda Bryant-Friedrich, PhD, Dean College of Graduate Studies The University of Toledo December 2019 Copyright 2019, Immaculate Sappy This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Ribonucleic Acids in Disease Etiology and Drug Discovery by Immaculate Sappy Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Medicinal Chemistry The University of Toledo December 2019 Pseudouridine (Ψ), the 5-ribosyl isomer of uridine (U) is the most abundant nucleic acid modification found in all domains of life and all types of RNA. Studies have shown that, urinary levels of pseudouridine are higher in Alzheimer’s Disease (AD) patients and that RNA oxidation is a major component in the pathogenesis of Alzheimer’s Disease (AD) and other neurodegenerative disorders. Therefore, there is a potential correlation between higher urinary levels of pseudouridine in AD patients and oxidative stress. Hence, subjecting pseudouridine to oxidative conditions may provide some key information about the role of this nucleoside in RNA related processes and its role in disease etiology. Besides neurodegenerative disorders, antibiotic resistance is an additional threat to human health.
    [Show full text]